SAN DIEGO, April 28, 2011 (GLOBE NEWSWIRE) -- Apricus Biosciences, Inc. ("Apricus Bio") (Nasdaq:APRI) announced today that it has filed a marketing application in Europe for Vitaros ® as a treatment ...

SAN DIEGO, May 19, 2011 (GLOBE NEWSWIRE) -- Apricus Biosciences, Inc. ("Apricus Bio") (Nasdaq:APRI) announced today that it will file a marketing application in Switzerland for Vitaros ® as a ...

Apricus Biosciences announced that the company has filed its response to questions received from Swissmedic, the Agency for Therapeutic Products in Switzerland, relating to its marketing application ...

Apricus Biosciences Inc (NASDAQ: APRI) receded 67.4 percent Friday and continued down Tuesday after the U.S. Food and Drug Administration issued a response letter for Vitaros. The FDA declined to ...

My news for Investors AtLeast one of the check box should be selected You are following news about Follow the latest news about APRI -- Potential Market Size for Vitaros® for Erectile Dysfunction in ...

(RTTNews) - Apricus Biosciences, Inc. (APRI) announced the outcome of its end-of-review meeting with the U.S. FDA on the New Drug Application for Vitaros (alprostadil), a topical cream for the ...

announced today its filing of a marketing application for Vitaros as a treatment for patients with erectile dysfunction in Switzerland, with Swissmedic, the Swiss Agency for Therapeutic Products. "We ...

Company Seeking Partner to Develop Vitaros in U.S. Company Evaluating Strategic Alternatives SAN DIEGO, April 16, 2018 (GLOBE NEWSWIRE) -- Apricus Biosciences, Inc. (Nasdaq:APRI), a biopharmaceutical ...

The Company has one approved product, Vitaros (R), for the treatment of erectile dysfunction, which is now approved in Europe and Canada and will be commercialized by Apricus Bio's marketing partners ...